⌕
Mannkind · MNKD · Nasdaq
Tenet 39 · Weak
Compare
$4.13−0.72%At closeTenet 39 · Weak
$4.13−0.03 (−0.72%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Mannkind (MNKD) Stock

Mannkind (MNKD) closed at $4.13 on Nov 13, 2026; its Tenet Score is 39 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

17 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$4.13
Nov 13, 2026
Market cap
$1.3B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
2.23 – 6.51
low → high
Tenet Score
39/100
Weak · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Mannkind Corp scores 39/100. Weak. Strongest on growth, financial health is the soft spot versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
39/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
29
Quality
38
Health
23
Growth
67

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityDHealthFGrowthCMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
3.2×
price to fiscal 2025 sales
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
11.1%
fiscal 2025, before interest and tax
Net margin
−18.1%
of revenue kept
Current ratio
2.22
current assets to liabilities
Net debt / EBITDA
13.0×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Mannkind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic c…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 59 US ETFs · top wrappers by weightSee all ETFs holding MNKD →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Mannkind in?

Mannkind is in the Healthcare sector and the Drugs industry.

What is Mannkind's Tenet Score?

Mannkind's Tenet Score is 39 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.